A common gain of function of p53 cancer mutants in inducing genetic instability

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Oncogene

• Publication date

  2010-02-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2009.376PMID 19881536PMCID PMC2837937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks

  2007cited by this paper
• Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

  2007cited by this paper
• p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

  2007cited by this paper
• Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

  2006cited by this paper
• Ser18 and 23 phosphorylation is required for p53‐dependent apoptosis and tumor suppression

  2006cited by this paper
• A global map of p53 transcription-factor binding sites in the human genome.

  2006cited by this paper
• DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis

  2006cited by this paper
• DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

  2005cited by this paper
• Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

  2005cited by this paper
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

  2004cited by this paper
• Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

  2004cited by this paper
• Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors.

  2003cited by this paper
• DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

  2003cited by this paper
• PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage

  2002cited by this paper
• Targeted disruption of NBS1 reveals its roles in mouse development and DNA repair

  2002cited by this paper
• Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool

  2001cited by this paper
• p53 and human cancer: the first ten thousand mutations.

  2000cited by this paper
• Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

  2000cited by this paper
• The absolute number of trans-rearrangements between the TCRG and TCRB loci is predictive of lymphoma risk: a severe combined immune deficiency (SCID) murine model.

  1997cited by this paper
• p53: puzzle and paradigm.

  1996cited by this paper

• A diabetes-induced change of MDM2 SNP309T→G contributes to aberrant retinal angiogenesis.

  2026cites this paper
• The impact of surgical resection in early onset colorectal cancer patients with liver limited disease.

  2026cites this paper
• Epi-nutrients for cancer prevention: Molecular mechanisms and emerging insights

  2025cites this paper
• Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as diagnostic tools

  2025cites this paper
• Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53

  2025cites this paper
• A clinical guide to TP53 mutations in myeloid neoplasms.

  2025cites this paper
• GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function

  2025cites this paper
• Mutant p53 upregulates HDAC6 to resist ER stress and facilitates Ku70 deacetylation, which prevents its degradation and mitigates DNA damage in colon cancer cells

  2025cites this paper
• A novel naphthoquinone compound triggers DNA damage-induced apoptosis on cholangiocarcinoma through upregulation of BAX

  2025cites this paper
• Divergent outcomes of neoadjuvant therapy for locally advanced small-cell lung cancer: two cases report and literature review

  2025cites this paper
• DNA Methylation of iNOS, eNOS, TP53 and LINE‐1 in Gingival Tissues of Cigarette Smokers, Heat‐Not‐Burn Smokers and Never Smokers: An Exploratory Study

  2025cites this paper
• Multihit Somatic Mosaicism of TP53 Pathogenic Variants in a Patient Mimicking Li-Fraumeni Syndrome.

  2025cites this paper
• Revealing the impact of autophagy-related genes in rheumatoid arthritis: Insights from bioinformatics

  2024cites this paper
• Targeting esophageal carcinoma: molecular mechanisms and clinical studies

  2024cites this paper
• Oncogenic R248W mutation induced conformational perturbation of the p53 core domain and the structural protection by proteomimetic amyloid inhibitor ADH-6.

  2024cites this paper
• Analysis of clinicopathological characteristics and prognostic factors in 54 metaplastic breast carcinoma patients from northwest China

  2024cites this paper
• MediatorWeb: a protein–protein interaction network database for the RNA polymerase II Mediator complex

  2024cites this paper
• Are TP53 mutations all alike?

  2024cites this paper
• Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer

  2023cites this paper
• PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53

  2023cites this paper
• p53 amyloid pathology with cancer grades and p53 mutations

  2023cites this paper
• CRISPR single base-editing: in silico predictions to variant clonal cell lines.

  2023cites this paper
• p53 amyloid pathology is correlated with cancer grades irrespective of the mutant or wildtype forms.

  2023cites this paper
• Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development.

  2023cites this paper
• New molecular targets in canine hemangiosarcoma-Comparative review and future of the precision medicine.

  2023cites this paper
• Dysregulated Signalling Pathways Driving Anticancer Drug Resistance

  2023cites this paper
• 2,2-Diphenethyl Isothiocyanate Enhances Topoisomerase Inhibitor-Induced Cell Death and Suppresses Multi-Drug Resistance 1 in Breast Cancer Cells

  2023influential citation
• Curcumin inhibits human cancer cell growth and migration through downregulation of SVCT2

  2023cites this paper
• Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability

  2022cites this paper
• Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery

  2022cites this paper
• Omics analyses of a somatic Trp53R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling

  2022cites this paper
• Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy

  2022cites this paper
• Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU via TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma

  2022cites this paper
• Discovery of a potent cytotoxic agent that promotes G2/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line.

  2022cites this paper
• The role of transcription factors in the acquisition of the four latest proposed hallmarks of cancer and corresponding enabling characteristics.

  2022cites this paper
• Effects of Berberine against Pancreatitis and Pancreatic Cancer

  2022cites this paper
• Network Analysis of Molecular Dynamics Sectors in the p53 Protein

  2022cites this paper
• Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

  2022cites this paper
• Li–Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype–phenotype correlation

  2022cites this paper
• Computational modeling of TP63-TP53 interaction and rational design of inhibitors: Implications for therapeutics.

  2022cites this paper
• Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion

  2021cites this paper
• Noncanonical roles of p53 in cancer stemness and their implications in sarcomas.

  2021cites this paper
• Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance

  2021influential citation
• The Function of the Mutant p53-R175H in Cancer

  2021cites this paper
• TP53 in Biology and Treatment of Osteosarcoma

  2021cites this paper
• The Effects of Ionising and Non-Ionising Electromagnetic Radiation on Extracellular Matrix Proteins

  2021cites this paper
• Role of p53 in transcriptional repression of SVCT2

  2021cites this paper
• Genetic associations of TP53 codon Pro72Arg polymorphism (rs1042522) in coronary artery disease: A meta-analysis of candidate genetic mutants

  2021cites this paper
• Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma

  2021cites this paper
• p53 mutations exhibit sex specific gain-of-function activity in gliomagenesis

  2021cites this paper
• Prognostic Values of E2F1/2 Transcriptional Expressions in Chromophobe Renal Cell Carcinoma Patients: Evidence from Bioinformatics Analysis

  2021cites this paper
• The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment

  2021cites this paper
• Adamantyl Isothiocyanates as Mutant p53 Rescuing Agents and Their Structure-Activity Relationships.

  2021cites this paper
• Sex- and Mutation-Specific p53 Gain-of-Function Activity in Gliomagenesis

  2021cites this paper
• Synthesis of 3-carbethoxy-4(3’-chloro-4’-hydroxy) phenyl-but-3-en-2-one and its cytotoxicity evaluation against cancer cell carrying mutant p53

  2021cites this paper
• Synthesis and biological evaluation of a novel anticancer agent CBISC that induces DNA damage response and diminishes levels of mutant-p53.

  2021cites this paper
• Allelic Expression Imbalance Analysis Identified YAP1 Amplification in p53- Dependent Osteosarcoma

  2021cites this paper
• Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy

  2021cites this paper
• Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)

  2021cites this paper
• Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit.

  2020cites this paper
• Toward Cancer Diagnostics of the Tumor Suppressor p53 by Surface Enhanced Raman Spectroscopy

  2020cites this paper
• TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer

  2020cites this paper
• Identifying multi-hit carcinogenic gene combinations: Scaling up a weighted set cover algorithm using compressed binary matrix representation on a GPU

  2020cites this paper
• 2-[(4-Hydroxybenzyl) Amino] Phenol (HBAP) Restores the Mutated p53 to the Level Similar to That of Wild-Type p53 Protein and Inhibits Breast Cancer Growth in vivo to by Inducing Tumor Cells Apoptosis

  2020cites this paper
• BRCA1/P53: Two strengths in cancer chemoprevention.

  2020cites this paper
• Homologs of the Tumor Suppressor Protein p53: A Bioinformatics Study for Drug Design.

  2020cites this paper
• Exploring the Landscape of Big Data Analytics Through Domain-Aware Algorithm Design

  2020cites this paper
• Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC

  2020cites this paper
• Mutant p53 in Cancer Progression and Targeted Therapies

  2020cites this paper
• Synthetic lethality between TP53 and ENDOD1

  2020cites this paper
• Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin

  2020cites this paper
• A Protein in the Yeast Saccharomyces cerevisiae Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor

  2020cites this paper
• Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation

  2020cites this paper
• Mutant p53 as an Antigen in Cancer Immunotherapy

  2020cites this paper
• p53’s Extended Reach: The Mutant p53 Secretome

  2020cites this paper
• Mutant p53 oncogenicity - dominant-negative or gain-of-function?

  2020cites this paper
• Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both?

  2020cites this paper
• PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells.

  2019cites this paper
• The impact of gut microbiota manipulation with antibiotics on colon tumorigenesis in a murine model

  2019cites this paper
• A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets

  2019cites this paper
• What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?

  2019cites this paper
• Role of p53 family isoforms in enhancing aggressiveness and chemoresistance in pancreatic cancer (Review)

  2019cites this paper
• MODELING CANCER USING LI-FRAUMENI SYNDROME PATIENT-DERIVED INDUCED PLURIPOTENT STEM CELLS

  2019cites this paper
• Diverse and cancer type-specific roles of the p53 R248Q gain-of-function mutation in cancer migration and invasiveness

  2019cites this paper
• Transcriptomic Signature of Radiation Response in Li-Fraumeni Syndrome

  2019cites this paper
• Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53

  2019cites this paper
• How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective

  2019cites this paper
• p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition

  2019cites this paper
• Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.

  2019cites this paper
• Metformin Inhibits Growth of Breast Cancer Cell T47 through Decreasing Expression of Protein P53, BCL2 and Cyclin D1

  2019cites this paper
• Descriptive analysis of genetic aberrations and cell of origin in Richter transformation

  2019cites this paper
• Natural Selection Between Two Games with Applications to Game Theoretical Models of Cancer

  2019cites this paper
• Genomic Copy Number Alterations in Serous Ovarian Cancer

  2018cites this paper
• Mutant p53 as a guardian of the cancer cell

  2018cites this paper
• Transcriptional Landscape of PARs in Epithelial Malignancies

  2018cites this paper
• TP53 single nucleotide polymorphism (rs1042522) in Iranian patients with coronary artery disease.

  2018cites this paper
• Impaired Notch Signaling Leads to a Decrease in p53 Activity and Mitotic Catastrophe in Aged Muscle Stem Cells.

  2018cites this paper
• Frequent Mutations in Natural Killer/T Cell Lymphoma

  2018cites this paper
• The transcription and expression profile of p53N236S mutant reveals new aspects of gain of function for mutant p53

  2018cites this paper
• Ultrasound‐guided intertumoral injection of contrast agents combined with human p53 gene for the treatment of breast cancer

  2018cites this paper